2025
Patterns of intra- and inter-tumor phenotypic heterogeneity in lethal prostate cancer
Roudier M, Gulati R, Sayar E, Patel R, Tratt M, Richards H, Cejas P, Gomez M, Qiu X, Xie Y, Hanratty B, Zaidi S, Zhao J, Adil M, Mittal C, Zhao Y, Dumpit R, Coleman I, Low J, Persse T, Galipeau P, Lee J, Tretiakova M, Chambers M, Vakar-Lopez F, True L, Perrone M, Lam H, Kollath L, Ding C, Harmon S, Cheng H, Yu E, Montgomery R, Hawley J, Lin D, Corey E, Schweizer M, Setty M, Ha G, Sawyers C, Morrissey C, Long H, Nelson P, Haffner M. Patterns of intra- and inter-tumor phenotypic heterogeneity in lethal prostate cancer. Journal Of Clinical Investigation 2025 PMID: 40493417, DOI: 10.1172/jci186599.Peer-Reviewed Original ResearchMetastatic prostate cancerLethal prostate cancerProstate cancerPhenotypic heterogeneityMetastatic prostate cancer patientsMolecularly heterogeneous diseaseTumor cell populationIntra-tumor heterogeneityCellular proliferation rateMetastatic sitesSingle-cell sequencing studiesMolecular subtypesClinical featuresTumor heterogeneityTumor phenotypeTumor samplesHeterogeneous diseaseClinical managementAnatomical sitesTherapeutic approachesSubtype heterogeneityPatientsTissue-basedCell populationsProliferation ratecGAS Expression is enhanced in systemic sclerosis associated interstitial lung disease and stimulates inflammatory myofibroblast activation.
Yu S, Hu B, Sun Y, Peng X, Lee C, Woo S, McGovern J, Zielonka J, Saber T, Ghincea A, Gandhi S, Walia A, Pivarnik T, Ishikawa G, Shao S, Sun H, Gunes B, Kujawski S, Perez S, Odell W, Hinchcliff M, Varga J, Feghali-Bostwick C, Sauler M, Gomez J, Ryu C, Herzog E. cGAS Expression is enhanced in systemic sclerosis associated interstitial lung disease and stimulates inflammatory myofibroblast activation. European Respiratory Journal 2025, 2401564. PMID: 40374521, DOI: 10.1183/13993003.01564-2024.Peer-Reviewed Original ResearchPrecision cut lung slicesSSc-ILD lung tissuesType 1 interferonSSc-ILDProduction of cytokinesBronchoalveolar lavageHuman precision cut lung slicesLung tissueLung fibroblastsLungs of patientsInterstitial lung diseasePulmonary fibrosis modelBleomycin mouse modelIsolated lung fibroblastsCultured fibroblastsPerturbs innate immunityFibrotic stimuliSingle cell RNA sequencing datasetsSystemic sclerosisHuman lung fibroblastsLung diseaseMouse modelCyclic GMP-AMP synthaseFibrosis modelTherapeutic approachesNew thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy
Dang S, Zhang X, Zhang Y, Zhang H. New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy. Autoimmunity Reviews 2025, 24: 103835. PMID: 40360014, DOI: 10.1016/j.autrev.2025.103835.Peer-Reviewed Original ResearchEnd-stage renal diseaseIgA nephropathyLack of effective early diagnosisPrognosis of patientsPathogenesis of IgANPathogenic IgAIntestinal flora dysbiosisImmune milieuMucosal infectionsEffective early diagnosisRetrospective reviewChronic glomerulonephritisRenal diseaseIgA depositionChronic progressionEarly diagnosisPathological featuresTherapeutic approachesPathogenic mechanismsIgANTherapeutic initiativesIgAIgA productionMesangial regionNephropathyLiver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
Sakuma I, Gaspar R, Nasiri A, Dufour S, Kahn M, Zheng J, LaMoia T, Guerra M, Taki Y, Kawashima Y, Yimlamai D, Perelis M, Vatner D, Petersen K, Huttasch M, Knebel B, Kahl S, Roden M, Samuel V, Tanaka T, Shulman G. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2502978122. PMID: 40310463, PMCID: PMC12067271, DOI: 10.1073/pnas.2502978122.Peer-Reviewed Original ResearchConceptsCholine-deficient l-amino acid-defined high-fat dietBempedoic acidLiver fibrosisLiver diseaseL-amino acid-defined high-fat dietAdvanced liver diseaseCholesterol contentHSD17B13 variantsHigh-fat dietTotal liver cholesterol contentTreated miceActivate signaling pathwaysVariant rs738409Liver cholesterol contentLiver lipidsFibrotic responsePromote inflammationTherapeutic approachesSteatotic liver diseaseDietary cholesterol supplementationFibrosisHuman liver samplesI148MAntisense oligonucleotidesProgressive formManagement of Challenging Psoriasis Clinical Scenarios
Stein Gold L, Alexis A, Glick B, Shahriari M, Song E, Strober B, Watch N, Young M. Management of Challenging Psoriasis Clinical Scenarios. Dermatology And Therapy 2025, 15: 1555-1567. PMID: 40232594, PMCID: PMC12092870, DOI: 10.1007/s13555-025-01393-3.Peer-Reviewed Original ResearchComorbidities associated with psoriasisPresentation of psoriasisSecondary treatment failureChronic inflammatory skin conditionInflammatory skin conditionTreatment failurePharmacological therapyTreat psoriasisPsoriasis treatmentSystemic diseaseTherapeutic approachesPsoriasisPsoriasis careQuality of lifeClinical practicePatientsSkin conditionsDermatology expertsComprehensive managementDarker skin tonesTreatmentA niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies
Mosialou I, Ali A, Labella R, Bisikirska B, Cuesta-Dominguez A, Vgenopoulou P, Reyes I, Rao S, Wang A, Luo N, Galan-Diez M, Zhao J, Chernak B, Bewersdorf J, Fukasawa K, Su J, Higa J, Adams R, Corper A, Pampou S, Woods C, Fan X, Shah R, Feldstein J, Liu N, Liang C, Heiblig M, Kornblau S, Garcia-Manero G, Berman E, Jurcic J, Rabadan R, Raza A, Kousteni S. A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. Cancer Cell 2025, 43: 1007-1024.e13. PMID: 40154481, PMCID: PMC12151774, DOI: 10.1016/j.ccell.2025.03.007.Peer-Reviewed Original ResearchConceptsStandard of careAcute myeloid leukemiaAll-trans-retinoic acidMyelodysplastic syndromeMyeloid malignanciesLeukemic micePatients treated with all-trans-retinoic acidMDS/AML cellsResponse to therapyResistance to standardResponse to ATRAMyeloid leukemiaTargeted therapyMyeloid cancersAssociated with activationMutation profilesTherapeutic approachesImproved efficacyDisease outcomeMiceRelapseMalignancyTherapyPatientsOsteoblastic cellsInteractions Between Commensal Microbes and Mosquito-Borne Viruses.
Zhu Y, Cao Y, Jiang L, Wang P, Cheng G. Interactions Between Commensal Microbes and Mosquito-Borne Viruses. Annual Review Of Virology 2025 PMID: 40067963, DOI: 10.1146/annurev-virology-092623-101222.Peer-Reviewed Original ResearchMosquito-borne virusesCommensal microbesMammalian hostsHost gut microbiotaInsect-specific virusesSymbiotic microbesEndosymbiotic bacteriaGut microbiotaRe-emerging mosquito-borne virusSkin microbiotaViral transmissionPathogenesis of viral infectionsMicrobesViral pathogenesisMicrobiotaVector competenceGlobal public healthHostMosquito-borne viral diseaseMosquito-borneImmune regulationTherapeutic approachesViral diseasesViral infectionIntricate interactionsPericardial Disease: Contemporary Techniques and Management
Bae J, Saleh A, Hu J, Setaro J, Altin S. Pericardial Disease: Contemporary Techniques and Management. Current Treatment Options In Cardiovascular Medicine 2025, 27: 23. DOI: 10.1007/s11936-025-01081-7.Peer-Reviewed Original ResearchTreatment of recurrent pericarditisManagement of pericardial diseasesImmunosuppressive therapyRecurrent pericarditisTransthoracic echocardiographySignificant management challengeRefractory casesRecurrence ratePericardial diseaseTherapeutic optionsPharmacological therapyTherapeutic advancesClinical trialsTherapeutic approachesPoor visualizationDiagnostic precisionTherapyPatientsDiseaseDiagnostic techniquesSymptom burdenEvidence-basedPatient careTransthoracicEchocardiographyCold and hot fibrosis define clinically distinct cardiac pathologies
Miyara S, Adler M, Umansky K, Häußler D, Bassat E, Divinsky Y, Elkahal J, Kain D, Lendengolts D, Flores R, Bueno-Levy H, Golani O, Shalit T, Gershovits M, Weizman E, Genzelinakh A, Kimchi D, Shakked A, Zhang L, Wang J, Baehr A, Petrover Z, Sarig R, Dorn T, Moretti A, Saez-Rodriguez J, Kupatt C, Tanaka E, Medzhitov R, Krüger A, Mayo A, Alon U, Tzahor E. Cold and hot fibrosis define clinically distinct cardiac pathologies. Cell Systems 2025, 16: 101198. PMID: 39970910, PMCID: PMC11922821, DOI: 10.1016/j.cels.2025.101198.Peer-Reviewed Original ResearchConceptsHeart failureMyocardial infarctionAutocrine growth factor loopsUnmet medical needCardiac fibrosisNeutralizing antibodiesReduced fibrosisTreatment strategiesMyofibroblast proliferationAcute MIFibrosis post-MICardiac pathologyFibrosisTherapeutic approachesPost-MIChronic injuryMyofibroblastsMedical needFactor loopsAcute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shimony S, Stahl M, Stone R. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management. American Journal Of Hematology 2025, 100: 860-891. PMID: 39936576, PMCID: PMC11966364, DOI: 10.1002/ajh.27625.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaTherapeutic management of acute myeloid leukemiaManagement of acute myeloid leukemiaEuropean Leukemia NetworkStem cell cancerTherapeutic decision-makingImmature leukemia cellsExtra-medullary tissuesMRD findingsPrognostic factorsCell cancerTherapeutic algorithmRisk classification algorithmApproved therapiesMyeloid leukemiaResponse assessmentRisk stratificationBone marrowTherapeutic managementMonitoring of disease statusPathophysiological understandingDisease characteristicsMolecular findingsTherapeutic approachesDisease statusExercise Pulmonary Hypertension and Beyond: Insights in Exercise Pathophysiology in Pulmonary Arterial Hypertension (PAH) from Invasive Cardiopulmonary Exercise Testing
Tarras E, Singh I, Kreiger J, Joseph P. Exercise Pulmonary Hypertension and Beyond: Insights in Exercise Pathophysiology in Pulmonary Arterial Hypertension (PAH) from Invasive Cardiopulmonary Exercise Testing. Journal Of Clinical Medicine 2025, 14: 804. PMID: 39941482, PMCID: PMC11818252, DOI: 10.3390/jcm14030804.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testingPulmonary arterial hypertensionCardiopulmonary exercise testingArterial hypertensionAssociated with pulmonary vascular remodelingExercise testRight heart failureExercise pulmonary hypertensionPulmonary vascular remodelingPulmonary hypertensionProgressive diseasePulmonary vasculatureTherapeutic optionsExercise pathophysiologyHigh morbidityHeart failureEarly diagnosisVascular remodelingTherapeutic approachesPersonalized treatmentHypertensionDisease subtypesDiagnosisSkeletal muscleDiseaseApplication of Stem Cells to Understanding Psychiatric Disorders
Birtele M, Quadrato G, Brennand K. Application of Stem Cells to Understanding Psychiatric Disorders. 2025, 53-64. DOI: 10.1093/med/9780197640654.003.0005.Peer-Reviewed Original ResearchPsychiatric disordersHuman induced pluripotent stem cellsAnimal models of autism spectrum disorderModel of autism spectrum disorderNeuroimaging studies of patientsModel psychiatric disordersAutism spectrum disorderStem cellsBipolar disorderDerivation of human induced pluripotent stem cellsNeuroimaging studiesApplication of stem cellsNeural processesSpectrum disorderStudy of patientsMental illnessPluripotent stem cellsDisordersComplex genetic risk factorsGenetic risk factorsTherapeutic approachesAnimal modelsNeural pathologyRisk factorsDisease predisposition
2024
Genetic and molecular drivers of scleroderma pathogenesis
Odell I. Genetic and molecular drivers of scleroderma pathogenesis. Clinics In Dermatology 2024, 43: 153-159. PMID: 39675445, PMCID: PMC12009687, DOI: 10.1016/j.clindermatol.2024.12.007.Peer-Reviewed Original ResearchGrowth factor signalingFactor signalingScleroderma pathogenesisActivated growth factor receptorsGenetic association studiesTherapeutic approachesMolecular driversHereditary hemorrhagic telangiectasiaAssociation studiesRegulatory genesGrowth factor receptorImmune regulatory genesGenetic studiesBiological insightsVascular endothelial cellsMolecular mechanismsHemorrhagic telangiectasiaImmune dysregulationClinical findingsVascular abnormalitiesHeterogeneous diseaseClinical phenotypeFactor receptorPatient phenotypesMultiple malignanciesDemographic diversity in platelet function and response to antiplatelet therapy
Jain K, Tyagi T, Gu S, Faustino E, Hwa J. Demographic diversity in platelet function and response to antiplatelet therapy. Trends In Pharmacological Sciences 2024, 46: 78-93. PMID: 39672782, PMCID: PMC11710996, DOI: 10.1016/j.tips.2024.11.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsResponse to antiplatelet therapyCardiovascular diseaseAntiplatelet therapyPlatelet biologyPathological platelet activationCardiovascular disease riskNon-genetic factorsPopulation-based differencesAntiplatelet strategiesPlatelet functionCardiovascular outcomesDiverse rolesPlatelet activationTherapeutic approachesTherapyPlateletBiologyTherapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 24: 171-189. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.Peer-Reviewed Original ResearchSide effect profileTrial end pointsCombination of therapeuticsReverse many aspectsFatty acid synthase inhibitorGenetic susceptibility factorsPlacebo responseEffect profileFibrosis reversalTreated patientsClinical studiesLiver inflammationSynthase inhibitorLiver diseaseTherapeutic approachesClinical useEnd pointsSteatotic liver diseaseTherapeutic landscapeMetabolic environmentHepatocyte deathSusceptibility factorsChronic overnutritionGlobal epidemicLiverWilson Disease: Novel Diagnostic and Therapeutic Approaches
Mariño Z, Schilsky M. Wilson Disease: Novel Diagnostic and Therapeutic Approaches. Seminars In Liver Disease 2024, 45: 221-235. PMID: 39496313, DOI: 10.1055/a-2460-8999.Peer-Reviewed Original ResearchWilson's diseaseTrials of gene therapyLiver biopsy specimensDried blood spotsCase of WDBiliary copper excretionBiopsy specimensGene therapyDiagnostic advancesMonitoring therapyWD diagnosisNewborn screeningLiver diseaseCopper excretionTherapeutic approachesBlood spotsTherapyTherapeutic objectivesDiseaseDiagnosisLiverCopper assayPatientsExcretionAssociation of sleep quality, smartphone addiction, and depressive symptoms among undergraduate medical students in Nepal
Paudel K, Shah S, Khanal P, Bhattarai M, Gautam K, Bhusal S, Bhandari P, Pandey A, Niroula S, Adhikari T, Shrestha R. Association of sleep quality, smartphone addiction, and depressive symptoms among undergraduate medical students in Nepal. Discover Psychology 2024, 4: 125. DOI: 10.1007/s44202-024-00246-y.Peer-Reviewed Original ResearchUndergraduate medical studentsMaharajgunj Medical CampusDepressive symptomsSleep qualityMedical studentsMedical CampusPatient Health Questionnaire-9Association of sleep qualityMethodsA cross-sectional studyPittsburgh Sleep Quality IndexCross-sectional studySleep Quality IndexIBM SPSS versionSmartphone addictionImpact of sleep qualityMental healthUnadjusted modelsSmartphone Addiction Scale-Short VersionSocio-demographicSPSS versionShort versionLongitudinal studyConclusionThis studyTherapeutic approachesQuality IndexMetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models
Karz A, Coudray N, Bayraktar E, Galbraith K, Jour G, Shadaloey A, Eskow N, Rubanov A, Navarro M, Moubarak R, Baptiste G, Levinson G, Mezzano V, Alu M, Loomis C, Lima D, Rubens A, Jilaveanu L, Tsirigos A, Hernando E. MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models. Pigment Cell & Melanoma Research 2024, 38: e13195. PMID: 39254030, PMCID: PMC11948878, DOI: 10.1111/pcmr.13195.Peer-Reviewed Original ResearchTumor contentMetastasis burdenMetastatic burdenTumor burdenMelanoma metastasesPreclinical modelsMurine modelPreclinical studiesMeasurable metastasesMelanoma researchTherapeutic approachesDeep neural networksHistopathological sectionsMechanisms of melanoma metastasisMetastasisHistological sectionsAI-based algorithmsAutomated quantificationWhole slide imagesAutomated quantitationNeural networkClass Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation
Ben-Yishay R, Globus O, Balint-Lahat N, Arbili-Yarhi S, Bar-Hai N, Bar V, Aharon S, Kosenko A, Zundelevich A, Berger R, Ishay-Ronen D. Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation. Cells 2024, 13: 1506. PMID: 39273076, PMCID: PMC11394433, DOI: 10.3390/cells13171506.Peer-Reviewed Original ResearchConceptsMEK inhibitorsBreast cancer cellsEpithelial-to-mesenchymal transitionCancer cellsPPARg agonistsDrug resistanceTherapeutic approachesTriple-negative breast cancerMurine breast cancer cellsAggressive breast cancer subtypeDevelopment of drug resistanceCancer cell plasticityBreast cancer subtypesCombination of pioglitazoneOvercome drug resistanceDedifferentiated cancer cellsBreast cancer progressionCancer cell differentiationCytoskeleton rearrangementLipid droplet accumulationCell trans-differentiationBreast cancerCancer subtypesCell plasticityTherapeutic strategiesManagement of recurrent and persistent malignant ovarian germ cell tumors: a narrative review
Nasioudis D, Pashankar F, Weller J. Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review. International Journal Of Gynecological Cancer 2024, 34: 1454-1460. PMID: 38991656, DOI: 10.1136/ijgc-2023-005052.Peer-Reviewed Original ResearchMalignant ovarian germ cell tumorsOvarian germ cell tumorsGerm cell tumorsCell tumorsHigh-dose chemotherapy protocolsPlatinum-resistant diseasePlatinum-sensitive diseaseSecondary cytoreductive surgeryPlatinum-based chemotherapyStandard dose chemotherapyCytoreductive surgeryDose chemotherapyTumor relapseOptimal resectionChemotherapy protocolsGenomic alterationsSpecialized centersTumorTherapeutic approachesSensitive diseasePatientsChemotherapyNarrative reviewOptimal timingDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply